Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
45 hedge funds and large institutions have $147M invested in Regulus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 3 closing their positions.
935% more capital invested
Capital invested by funds: $14.2M → $147M (+$133M)
633% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 3
582% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $163K
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more funds holding
Funds holding: 26 → 45 (+19)
24.59% more ownership
Funds ownership: 54.97% → 79.56% (+25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.15M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.37M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$66K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$46.4K |
| 3 |
GC
Grimes & Company
Westborough,
Massachusetts
|
-$254 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$68 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$47 |
RGLS Hedge Fund Activity: Q1 2024 in Review
45 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2024, worth a combined $147M — up 935% from $14.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RGLS positions and 3 closed out — a net gain of 19 holders — while 14 added to existing stakes and 4 trimmed.
The largest buyer was Federated Hermes, adding an estimated $14.6M. The largest seller was DAFNA Capital Management, cutting an estimated $66K.
- 45 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2024, up from 26 in Q4 2023.
- Funds reported $147M of Regulus Therapeutics stock for Q1 2024, up 935% quarter-over-quarter.
- 22 funds opened new Regulus Therapeutics positions in Q1 2024 and 3 closed out, a net change of +19 holders.
- The largest Regulus Therapeutics buyer in Q1 2024 was Federated Hermes, an estimated $14.6M added.
- The largest Regulus Therapeutics seller in Q1 2024 was DAFNA Capital Management, an estimated $66K sold.
Based on aggregated 13F filings for Q1 2024.